Edesa Biotech, Inc. (EDSA)

$2.06

+0.03 (+1.48%)
Rating:
Recommendation:
-
Symbol EDSA
Price $2.06
Beta 1.581
Volume Avg. 0.07M
Market Cap 31.852M
Shares () -
52 Week Range 1.3-12.0
1y Target Est -
DCF Unlevered EDSA DCF ->
DCF Levered EDSA LDCF ->
ROE -140.43% Strong Sell
ROA -105.02% Strong Sell
Operating Margin -
Debt / Equity 48.19% Neutral
P/E -
P/B 2.41 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EDSA news


Dr. Pardeep Nijhawan
Healthcare
Biotechnology
NASDAQ Capital Market

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.